TMO
Thermo Fisher Scientific Inc.
- Stock-based compensation, 2025
- $310M
- YoY, 2025
- +3.0%
- 5-year CAGR
- +9.6%
- 10-year CAGR
- +9.5%
Stock-based compensation
Stock-based compensation by fiscal year
| Period | Stock comp | YoY |
|---|---|---|
| 2025 | $310M | +3.0% |
| 2024 | $301M | +8.3% |
| 2023 | $278M | −9.4% |
| 2022 | $307M | +33.5% |
| 2021 | $230M | +17.3% |
| 2020 | $196M | +8.3% |
| 2019 | $181M | 0.0% |
| 2018 | $181M | +13.8% |
| 2017 | $159M | +19.5% |
| 2016 | $133M | +6.4% |
| 2015 | $125M | +6.7% |
| 2014 | $117M | +28.8% |
| 2013 | $91M | +16.2% |
| 2012 | $78M | −2.2% |
| 2011 | $80M | −2.0% |
| 2010 | $82M | +21.8% |
| 2009 | $67M | +17.3% |
| 2008 | $57M | +11.7% |
| 2007 | $51M | — |